Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?-Reference-Cited by-同舟云学术

Metastatic Breast Cancer: Overall Survival Related to Successive Chemotherapies. What Do We Gain After the Third Line?

Published:2009-01 Issue:1 Volume:27 Page:81-85
ISSN:0735-7907
Container-title:Cancer Investigation
language:en
Short-container-title:Cancer Investigation

Author:

Tacca Olivier,LeHeurteur Marianne,Durando Xavier,Mouret-Reynier Marie-Ange,Abrial Catherine,Thivat Emilie,Bayet-Robert Mathilde,Penault-Llorca Frederique,Chollet Phillippe

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,General Medicine

Link

http://www.tandfonline.com/doi/pdf/10.1080/07357900802290580

Reference13 articles.

1. Ten-year follow-up study of premenopausal women with metastatic breast cancer: an Eastern Cooperative Oncology Group study.

2. Should we dream the impossible dream? The meaning of long-term survival in metastatic breast cancer.

3. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?

4. Salvage therapies in women who fail to respond to first-line treatment with fluorouracil, epirubicin, and cyclophosphamide for advanced breast cancer.

5. Response to chemotherapy is a major parameter-influencing long-term survival of metastatic breast cancer patients

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Does the Timing of Eribulin Treatment for Advanced or Metastatic Breast Cancer Matter? Evidence from a Real-World Setting;Chemotherapy;2022-09-15

2. Clinical utility of circulating tumour cell-based monitoring of late-line chemotherapy for metastatic breast cancer: the randomised CirCe01 trial;British Journal of Cancer;2021-01-21

3. The role of chemotherapy in treatment of advanced breast cancer: an overview for clinical practice;Critical Reviews in Oncology/Hematology;2020-09

4. Secondary analyses of the randomized phase III Stop&Go study: efficacy of second-line intermittent versus continuous chemotherapy in HER2-negative advanced breast cancer;Acta Oncologica;2020-03-06

5. Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimens;Breast Cancer Research and Treatment;2018-10-24